Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NUVL 
Nuvalent Inc (NUVL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: NUVL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $141.82
1 Year Target Price $141.82
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.5% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.74B USD | Price to earnings Ratio - | 1Y Target Price 141.82 |
Price to earnings Ratio - | 1Y Target Price 141.82 | ||
Volume (30-day avg) 11 | Beta 1.31 | 52 Weeks Range 55.53 - 112.88 | Updated Date 12/2/2025 |
52 Weeks Range 55.53 - 112.88 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.33 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -1.36 | Actual -1.7 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.96% | Return on Equity (TTM) -38.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7548713021 | Price to Sales(TTM) - |
Enterprise Value 7548713021 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.26 | Shares Outstanding 67271461 | Shares Floating 42928953 |
Shares Outstanding 67271461 | Shares Floating 42928953 | ||
Percent Insiders 2.56 | Percent Institutions 103.03 |
Upturn AI SWOT
Nuvalent Inc
Company Overview
History and Background
Nuvalent, Inc. is a biotechnology company founded in 2021. It is focused on developing precisely targeted therapies for cancer patients. The company went public in 2021.
Core Business Areas
- Precision Oncology Drug Development: Nuvalent focuses on creating small molecule kinase inhibitors that are highly selective for specific cancer-driving mutations, aiming to improve efficacy and reduce off-target side effects.
Leadership and Structure
Nuvalent is led by its CEO, James Porter. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- NVL-520: A ROS1-selective tyrosine kinase inhibitor (TKI) designed to address resistance mutations and brain penetration challenges in ROS1-positive non-small cell lung cancer (NSCLC) and other cancers. The drug is in clinical trials. Competitors: Entrectinib (Rozlytrek), Crizotinib (Xalkori).
- NVL-655: An ALK-selective TKI for ALK-positive NSCLC, designed to overcome resistance mutations. Currently in clinical trials. Competitors: Alectinib (Alecensa), Lorlatinib (Lorbrena).
- NVL-688: A novel oral selective inhibitor of the HER2 exon 20 insertion for breast cancer. Currently in clinical trials.
Market Dynamics
Industry Overview
The oncology market is characterized by rapid innovation, high regulatory hurdles, and intense competition. Precision oncology is a growing segment focused on targeted therapies based on specific genetic mutations or biomarkers.
Positioning
Nuvalent is positioned as a precision oncology company focusing on highly selective kinase inhibitors to overcome drug resistance and improve patient outcomes. Its competitive advantage lies in its rational drug design approach and focus on addressing unmet needs in specific cancer subtypes.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is substantial and growing. Estimates place the global oncology drug market at hundreds of billions of dollars. Nuvalent targets specific subsets of cancers with defined genetic alterations, aiming to capture a significant share within those segments.
Upturn SWOT Analysis
Strengths
- Strong pipeline of selective kinase inhibitors
- Experienced management team
- Rational drug design approach
- Focus on addressing drug resistance
Weaknesses
- Clinical trial risks and uncertainties
- High cash burn rate
- Reliance on successful clinical development
- Limited commercialized products
Opportunities
- Potential for breakthrough therapies in targeted oncology
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in diagnostic technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Failure of clinical trials
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ROSE
- LLY
- TAK
Competitive Landscape
Nuvalent competes with larger pharmaceutical companies that have established oncology franchises. Its advantage lies in its focus on specific drug resistance mechanisms and its rational drug design approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by preclinical data development and early clinical trials
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates are subject to change based on clinical data and market conditions.
Recent Initiatives: Recent initiatives include advancing NVL-520 and NVL-655 through clinical trials and expanding the pipeline with new drug candidates.
Summary
Nuvalent is a promising precision oncology company with a focus on developing selective kinase inhibitors. The company's strength lies in its targeted approach and experienced team. However, it faces typical biotech risks related to clinical trials and regulatory approval. Nuvalent should focus on successful clinical trial outcomes and strategic partnerships to maximize its potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and clinical trial outcomes are uncertain. Market share percentages are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvalent Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-29 | CEO, President & Director Dr. James R. Porter Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 218 | Website https://www.nuvalent.com |
Full time employees 218 | Website https://www.nuvalent.com | ||
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.